Bavarian Nordic A/S reports Q3 results; updates FY outlook
Source: SeekingAlpha
2025-11-14 04:04:02 ET
More on Bavarian Nordic A/S
- Bavarian Nordic A/S 2025 Q2 - Results - Earnings Call Presentation
- Bavarian Nordic A/S (BVNKF) Q2 2025 Earnings Call Transcript
- Bavarian Nordic draws higher bid for take-private deal
- First locally-acquired chikungunya case reported in U.S. since 2019
- Seeking Alpha’s Quant Rating on Bavarian Nordic A/S
Read the full article on Seeking Alpha
For further details see:
Bavarian Nordic A/S reports Q3 results; updates FY outlook
Bavarian Nordic R/I Ord
NASDAQ: BVNKF
BVNKF Trading
0.0% G/L:
$30.62 Last:
150 Volume:
$30.62 Open:
BVNKF Latest News
July 28, 2025 02:08:04 am
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic
July 22, 2025 02:00:00 am
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine
June 18, 2025 03:03:59 am
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
BVNKF Stock Data
$2,379,362,265
78,097,834
N/A
N/A
Biotechnology & Life Sciences
Healthcare
DK
Kvistgaard
